Substance / Medication

Tenofovir alafenamide

Overview

Active Ingredient
tenofovir alafenamide
RxNorm CUI
1721603

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

16 trials linked to this intervention

16
Total Trials
8
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis.
Luo Jian-Xing, Chen Guo, Hu Xiao-Yu et al. · Gastroenterol Hepatol · 2025
PMID: 39426790Meta-Analysis
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta-Analysis.
Hsu Ping-Yu, Su Hui-Chen, Ma Mi-Chia et al. · J Med Virol · 2025
PMID: 40195938Meta-Analysis
Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: a systematic review and meta‑analysis.
Gräfe Marlen, Schäfer Marie S, Leithner Christoph et al. · Pol Arch Intern Med · 2024
PMID: 39387623Meta-Analysis
A systematic review and meta-analysis of maternal weight changes and pregnancy outcomes associated with integrase inhibitors and tenofovir alafenamide in pregnant women with HIV.
Eke Ahizechukwu Chigoziem, Ramaiyer Malini, Eleje George Uchenna et al. · Am J Obstet Gynecol MFM · 2024
PMID: 38866134Meta-AnalysisFull text (PMC)
Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis.
Huang Ji, Cheng Cong, Li Kangxin et al. · Dig Dis Sci · 2024
PMID: 38341392Meta-Analysis
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.
Yoo Jeong-Ju, Jung Eun Ae, Kim Sang Gyune et al. · J Int AIDS Soc · 2024
PMID: 39301685Meta-AnalysisFull text (PMC)
Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.
O'Rourke John, Townsend Claire L, Milanzi Edith et al. · J Int AIDS Soc · 2023
PMID: 36823283Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tenofovir alafenamide (substance)
SNOMED CT
715220007
UMLS CUI
C3713958
RxNorm CUI
1721603

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
16
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.